← Back to Search

Calcium Channel Blocker

Moxonidine + Amlodipine for Obesity

Phase 1
Waitlist Available
Led By Italo Biaggioni, MD
Research Sponsored by Italo Biaggioni
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 hours
Awards & highlights

Study Summary

This trial will study the effects of a sympathetic inhibitor on obese people with high blood pressure to see if it improves insulin sensitivity, inflammation, and endothelial function.

Eligible Conditions
  • Obesity-Associated Insulin Resistance

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Insulin Sensitivity

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: MoxonidineExperimental Treatment1 Intervention
Moxonidine to be administered at a dose to produce a decrease in BP of at least 20% of baseline for 9 weeks
Group II: AmlodipineActive Control1 Intervention
Amlodipine to be administered at a dose to produce a decrease in BP of at least 20% of baseline for 9 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Moxonidine
FDA approved

Find a Location

Who is running the clinical trial?

Italo BiaggioniLead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)NIH
3,833 Previous Clinical Trials
47,306,424 Total Patients Enrolled
47 Trials studying Insulin Resistance
11,513 Patients Enrolled for Insulin Resistance
Italo Biaggioni, MDPrincipal Investigator - Vanderbilt University Medical Center
Vanderbilt University Medical Center
28 Previous Clinical Trials
1,382 Total Patients Enrolled
1 Trials studying Insulin Resistance
19 Patients Enrolled for Insulin Resistance

Media Library

Amlodipine 5 MG (Calcium Channel Blocker) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04329806 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are elderly individuals eligible to participate in this experiment?

"The maximum age limit for this trial is 65, while the minimum required to participate is 18."

Answered by AI

Could you please elucidate on the safety profile of Moxonidine 0.2 MG for human use?

"Our in-house medical team has determined that Moxonidine 0.2 MG is relatively safe, scoring a 1 since the research phase of this medication only provides limited data regarding safety and efficacy."

Answered by AI

How many participants has been deemed eligible for this research trial?

"Affirmative. Clinicaltrials.gov has identified this research as actively seeking volunteers, with the trial commencing on February 23rd 2021 and updated August 21st 2022. The study is currently recruiting 72 patients from a single medical centre."

Answered by AI

Are there any other previous investigations done using Moxonidine 0.2 MG?

"Currently,32 scientific investigations involving Moxonidine 0.2 MG are actively being conducted with 6 of those trials in Phase 3. Despite much of the research centered around Boston, Massachusetts, there are 321 medical centres throughout North America conducting these clinical experiments."

Answered by AI

What symptoms does Moxonidine 0.2 MG typically address?

"Moxonidine 0.2 MG is a pharmaceutical used to combat cardiovascular conditions such as dyslipidemias, CAD (coronary artery disease), and heightened risk of cardiac events."

Answered by AI

Is it possible for me to partake in this medical experiment?

"To be eligible for this medical trial, aspiring participants must possess insulin and have an age range between 18-65. Thus far, 72 individuals have been recruited to the study."

Answered by AI

Are there any vacancies for individuals to join this trial?

"Confirmed, according to information hosted on clinicaltrials.gov this medical study is still seeking participants as of August 21st 2022. The trial was first posted on February 23rd 2021 and requires 72 individuals from a single location."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Sympathetic Mechanisms in the Cardiovascular and Metabolic Alterations of Obesity
Italo Biaggioni 2021. "Sympathetic Mechanisms in the Cardiovascular and Metabolic Alterations of Obesity". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04329806.
~16 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top